University Hospital, Lille — Biomedical Watch V2

Traitements4programmes

Essais4liés

Publications4liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
deferiproneDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Parkinson, Sclérose latérale amyotrophique	Phase 2/3	Neuroprotection	France	À vérifier
deferiproneDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	Neuroprotection	France	À vérifier
deferipronePeripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development. The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo. PBMC and platelets will be stored for future analyses.	Parkinson	Phase 2/3	Neuroprotection	France	À vérifier
deferiproneDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Phase 2/3	Neuroprotection	France	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
deferiprone	Sclérose latérale amyotrophique	Phase 2/3	NCT03293069	FAIR-ALS II — Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis	COMPLETED
deferiprone	Parkinson	Phase 2/3	NCT00943748	FAIR-PARK-I — Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease	COMPLETED
deferiprone	Sclérose latérale amyotrophique	Non applicable	NCT02880033	LymphoEnergy — Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes	COMPLETED
MRI	Myopathies	À vérifier	NCT04656210	Myotonic Dystrophy - Vascular and Cognition	ACTIVE_NOT_RECRUITING

Publications

4

Molécule	Indication / population	Titre	Journal	Date
deferiprone		Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice.	American journal of hematology
deferiprone		Trace Elements Dyshomeostasis and Toxic Metals Neurotoxicity in Neurodegenerative Diseases.	Biological trace element research
deferiprone		Precision Medicine in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia: Toward Personalized Diagnosis and Therapy.	Hemoglobin
deferiprone		Amelioration of Cisplatin Nephrotoxicity by Fe-Pt Coordination Exchange-Triggered Ferroptosis Suppression.	Advanced healthcare materials